Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia

• Published in: Clinical and translational gastroenterology 2019-04, Vol.10 (4), p.e00029-e00029
• Main Authors: Vila-Navarro, Elena, Duran-Sanchon, Saray, Vila-Casadesús, Maria, Moreira, Leticia, Ginès, Àngels, Cuatrecasas, Miriam, Lozano, Juan José, Bujanda, Luis, Castells, Antoni, Gironella, Meritxell
• Format: Article
• Language: English
• ISSN: 2155-384X; 2155-384X
• DOI: 10.14309/ctg.0000000000000029

Pancreatic ductal adenocarcinoma (PDAC) presents the lowest survival rate of all cancers because only 6% of patients reach five-year survival. Alterations in the expression of several microRNAs (miRNAs) occur in the tumor of PDAC and in preneoplastic lesions as the called intraductal papillary mucinous neoplasm (IPMN). Here, we aimed at identifying which miRNAs are significantly altered in liquid biopsies from patients with PDAC and IPMN to find new noninvasive biomarkers for early detection of PDAC. We analyzed by real-time quantitative reverse transcription-PCR (qRT-PCR) the expression of 17 circulating miRNAs, previously found to be significantly overexpressed in tissue pancreatic neoplasms, in a set of 182 plasma samples (94 PDAC, 19 IPMN, 18 chronic pancreatitis, and 51 disease-free controls). Then, we analyzed CA19.9 levels in the same plasma set, and we assessed the diagnostic values of differentially expressed miRNAs, CA19.9, and all possible combinations. Of note, 16, 14, and 9 miRNAs were significantly increased in PDAC, IPMN, and chronic pancreatitis, respectively, compared with control plasmas. miR-21-5p, miR-33a-3p, miR-320a, and miR-93-5p showed the highest discriminating capacity for pancreatic neoplasia (PDAC or IPMN) with an area under the receiver operating characteristic curve (AUC) of 0.86, 0.85, 0.85, and 0.80, respectively. 2-miRNA combinations improved these performances reaching AUC = 0.90 for "miR-33a-3p+miR-320a." Addition of CA19.9 increased the diagnostic potential of miRNA signatures even further achieving an AUC of 0.95 (93% sensitivity and 85% specificity) for the combination of "miR-33a-3p+miR-320a+CA19.9." Novel signatures combining miRNAs and CA19.9 could be used as noninvasive biomarkers for early detection of PDAC.